-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Patient Advocacy & Survivorship
-
Knowing Before We Can Act: The Value of MRD Testing From a Patient’s Perspective
While MRD testing does not eliminate the uncertainty of recurrence, Jan Pezarro explains how advanced molecular testing provides invaluable clarity for patients.
-
The Importance of Compassion and Clear Communication: A Patient Advocate Perspective
Patient advocate Kate Sinclair shares why communication is one of the most important tools for improving the patient experience during their lung cancer journey.
-
Patient Charts: How to Carefully Manage Patient Access to Health Information
Advocate Angus Pratt explores the pros and cons of patient access to electronic health records and discusses how the emergence of AI—with human oversight—could offer a way to navigate this complex issue.
-
Lost in Translation: Survey Reveals Critical Communication Gaps in Lung Cancer Care
Complex information and poor communication were identified as major obstacles to meaningful participation in decision-making, according to data presented by patient advocate Debra Montague.
-
More Than a Partnership: How Oncogene-Driven Patient Groups Are Mobilizing the Global Community to Drive Research
It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way since the discovery of the first EGFR mutation in lung cancer in 2004.2 ,3 Even amid the challenges of the global COVID-19 pandemic, the lung…
-
Veterans Health Administration’s Lung Precision Oncology Program Helps Individualize Treatment
Lung cancer is not only the leading cause of cancer deaths in the United States, with nearly 229,000 people diagnosed annually, but is also the deadliest cancer affecting patients of the Veterans Health Administration (VHA). More than 900,000 Veterans are at risk of developing lung cancer because of advanced age, environmental exposures, and/or smoking, according…
-
Awareness-raising Bike Ride in The Netherlands Connected Hospitals, Patients
Patients and supporters cycled nearly 1,150 kilometers through The Netherlands on May 21, 2021 in a “White Ribbon Tour” to raise awareness for lung cancer. The grassroots event was organized by Niels Harthoorn, age 22, an industrial engineering and management student at the University of Twente, and a patient with lung cancer. For the ride,…
-
Survivorship in Lung Cancer: An Interview With Dr. Anne Katz
Anne Katz, PhD, RN, FAAN, is a certified sexuality counselor and clinical nurse specialist at Cancer Care Manitoba, Winnipeg, Canada, and the author of multiple books on cancer survivorship. In the following article, Dr. Katz discusses lung cancer survivorship challenges as well as considerations that providers should take to ensure that this population is receiving…
-
Lung Cancer Health Care Delivery, Community Building, and Research: Are They Truly Inclusive?
Lung cancer was first identified as a distinct disease in 1761.1 Since this discovery, we have come a long way—both in terms of progress towards understanding the heterogeneous biology of the disease and translating this understanding into action by development of new treatments.2 Indeed, since 2015, the United States Food and Drug Administration (FDA) has…
-
Ending Stigma in Lung Cancer: The IASLC Participates in a Collaborative Summit Held by the National Lung Cancer Roundtable
Stigma is any thinking or behavior that produces internal shame or external judgment toward a person, place, or thing.1 In healthcare, stigma could be any sociocultural norm that prevents a patient’s access to or experience of high-quality care. With lung cancer in particular, patients often feel stigmatized by clinicians, patients, family, friends, and within themselves…
View ILCN Archives
Provider Resources
Popular Articles